South San Francisco-based Amphivena Therapeutics Inc, a developer of T cell engager therapeutics for cancer, has raised $62 million in Series C financing. NanoDimension and Qiming Venture Partners USA led the round.
Source: Press Release
South San Francisco-based Amphivena Therapeutics Inc, a developer of T cell engager therapeutics for cancer, has raised $62 million in Series C financing. NanoDimension and Qiming Venture Partners USA led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: